Working… Menu

Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03291197
Recruitment Status : Completed
First Posted : September 25, 2017
Results First Posted : September 30, 2019
Last Update Posted : September 30, 2019
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
Shoulder-hand syndrome (SHS) in stroke patients is painful and lowers quality of life. Unfortunately, the cause of SHS is not known, diagnosing SHS can be difficult, and treating it can be hard. Recent research has shown that certain nerve blocks are good for treating shoulder pain for stroke patients, but no one has looked specifically as SHS. Investigators think that specific nerve blocks involving a shoulder nerve (the suprascapular, or SSc nerve) and a hand nerve (the median nerve) will be helpful in reducing SHS pain. Investigators will use ultrasound guidance to accurately inject these nerves. These injections have never been described for SHS patients however, so investigators want to make sure people with SHS can go through with the injections without too much pain or discomfort. That is, the investigators want to test the tolerance of these injections for people with SHS. Investigators are also hoping to better understand how consistent a set of diagnostic criteria, called the Budapest criteria, are at diagnosing SHS in order to be able to accurately diagnose this condition.

Condition or disease Intervention/treatment Phase
Shoulder Hand Syndrome Complex Regional Pain Syndromes Drug: Suprascapular and median nerve blocks Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label preliminary study testing the tolerability of the procedure.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Assessing the Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome - a Feasibility Study
Actual Study Start Date : October 15, 2017
Actual Primary Completion Date : October 14, 2018
Actual Study Completion Date : October 14, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open label treatment
These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
Drug: Suprascapular and median nerve blocks
Ultrasound guided injection of the median and suprascapular nerve of the affected side.
Other Name: Bupivacaine, kenalog

Primary Outcome Measures :
  1. Number of Participants Demonstrating Tolerability of Suprascapular and Median Nerve Blocks [ Time Frame: 12 months ]
    To evaluate the tolerability of ultrasound-guided suprascapular and median nerve blocks in stroke patients with SHS as determined using the Budapest criteria. Since tolerability is a subjective measure, it will be defined by a composite outcome including: A) Pain score prior to, during, and immediately following the procedure as measured by the visual analog scale (VAS); B) the rate of serious adverse events associated with this procedure; and C) the level of patient acceptance and satisfaction as determined by a validated post-procedure survey.

  2. Visual Analog Scale (VAS) [ Time Frame: measured at baseline, within 1 hour after, and 2 weeks post intervention ]
    Pain scale used to address a difference following intervention. Pain is measured on a horizontal line from 0 to 100mm, with 0 being no pain and 100 being the worst imaginable pain. Participants place a vertical mark on the line indicating their pain intensity.

Secondary Outcome Measures :
  1. Inter-rater Agreement of Budapest Criteria [ Time Frame: 12 months ]
    Investigators will assess the reproducibility of the Budapest clinical criteria for newly suspected cases of SHS. This will be achieved by determining the level of inter-rater agreement between a resident and a staff physician working in stroke rehabilitation. Investigators will thus determine if there is variability in the clinical diagnosis among physicians with different levels of expertise.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects are required to be 18 years of age or older and have a presumptive diagnosis of SHS post-stroke with a minimum visual analog scale of 40mm (greater than 40mm is considered moderate pain).

Exclusion Criteria:

  • Subjects will be excluded from the study if they have significant cognitive impairment (mini-mental state examination <23) and language deficits (difficulty cooperating due to aphasia) as this may affect their response to the outcome measures. Subjects with uncontrolled hypertension (>180/110), septicemia, and brachial plexus injuries will be excluded. Patients who are blind and deaf will also be excluded, as they will be unable to adequately complete the post-procedure survey and VAS. Patients on anticoagulation medications will also be excluded on a case-by-case basis and medications will be held prior to injection if required for safety. Patients with INR >1.5 will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03291197

Layout table for location information
Canada, Ontario
Elisabeth Bruyere Hospital
Ottawa, Ontario, Canada, K1N5C8
Sponsors and Collaborators
Ottawa Hospital Research Institute
Layout table for investigator information
Principal Investigator: T Mark Campbell, MD Ottawa Hospital Research Institute
  Study Documents (Full-Text)

Documents provided by Ottawa Hospital Research Institute:
Layout table for additonal information
Responsible Party: Ottawa Hospital Research Institute Identifier: NCT03291197    
Other Study ID Numbers: 20170066-01H
First Posted: September 25, 2017    Key Record Dates
Results First Posted: September 30, 2019
Last Update Posted: September 30, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ottawa Hospital Research Institute:
Suprascapular nerve block
Median nerve block
Shoulder hand syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Complex Regional Pain Syndromes
Reflex Sympathetic Dystrophy
Pathologic Processes
Autonomic Nervous System Diseases
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents